User Tools
4dn:phase2:working_groups:cell_lines_and_samples
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
4dn:phase2:working_groups:cell_lines_and_samples [2022/05/13 06:28] oh |
4dn:phase2:working_groups:cell_lines_and_samples [2025/04/22 16:21] (current) |
||
|---|---|---|---|
| Line 65: | Line 65: | ||
| **Tier 1 Lines - CLICK ON LINE FOR THE LATEST 4DN GROWTH SOP NECESSARY FOR GOLD STANDARD DATA PRODUCTION!!! NOTE: For cell lines that use FBS, use the negotiated 4DN lot of FBS. **Brief 4DN history of Tier1 lines is provided. The top priorities for Tier1 were that they have a (relatively) stable karyotype and can be expandable to large numbers. Secondary issues that excluded lines from Tier1 were onerous MTAs or licences (e.g. Geron hTERT plasmid construct in RPE), derivation from tumors (e.g. HCT116), lack of consent for public sharing of raw DNA sequence reads and mouse cells. 4DN Cells WG is always willing to consider any changes or any additions to Tiered cells line (Tier1 or Tier2). | **Tier 1 Lines - CLICK ON LINE FOR THE LATEST 4DN GROWTH SOP NECESSARY FOR GOLD STANDARD DATA PRODUCTION!!! NOTE: For cell lines that use FBS, use the negotiated 4DN lot of FBS. **Brief 4DN history of Tier1 lines is provided. The top priorities for Tier1 were that they have a (relatively) stable karyotype and can be expandable to large numbers. Secondary issues that excluded lines from Tier1 were onerous MTAs or licences (e.g. Geron hTERT plasmid construct in RPE), derivation from tumors (e.g. HCT116), lack of consent for public sharing of raw DNA sequence reads and mouse cells. 4DN Cells WG is always willing to consider any changes or any additions to Tiered cells line (Tier1 or Tier2). | ||
| - | [[https://drive.google.com/file/d/1Cxg8LZaPuIRpKbrtah0zfeVPO7Eyqqtt/view?usp=sharing|H1]] male hESC line | + | [[https://drive.google.com/file/d/1SKnx1XE7eYCdC61wECZxZ28_WWhmlpJh/view?usp=sharing|H1]] male hESC line |
| **<font 11.0pt/inherit;;inherit;;inherit><font inherit/";inherit;;inherit><font inherit/inherit;;black;;inherit>WA01 (aka H1)</font></font></font>** <font 11.0pt/inherit;;inherit;;inherit><font inherit/";inherit;;inherit><font inherit/inherit;;black;;inherit>was chosen due to its abundance of genomics data. Human ESCs offer differentiation toward many different cell lineages. Cells are immortal, and methods for genome engineering are continuously improving. Both fixed and live imaging have been achieved and the motility of the cells has been addressed with cell density and ROCK inhibition. One disadvantage is that they are more challenging to grow and particularly to maintain in an undifferentiated state but in some cases experienced labs could provide fixed material to less experienced labs.</font></font></font> | **<font 11.0pt/inherit;;inherit;;inherit><font inherit/";inherit;;inherit><font inherit/inherit;;black;;inherit>WA01 (aka H1)</font></font></font>** <font 11.0pt/inherit;;inherit;;inherit><font inherit/";inherit;;inherit><font inherit/inherit;;black;;inherit>was chosen due to its abundance of genomics data. Human ESCs offer differentiation toward many different cell lineages. Cells are immortal, and methods for genome engineering are continuously improving. Both fixed and live imaging have been achieved and the motility of the cells has been addressed with cell density and ROCK inhibition. One disadvantage is that they are more challenging to grow and particularly to maintain in an undifferentiated state but in some cases experienced labs could provide fixed material to less experienced labs.</font></font></font> | ||
| Line 177: | Line 177: | ||
| **hPSC REAGENT INFORMATION** | **hPSC REAGENT INFORMATION** | ||
| - | [[https://drive.google.com/file/d/1vlUXqE4YcrxTtxT6-tLf-MOP8K2-KsE1/view?usp=sharing|Stem Cell Tech Quote, which contains ordering instructions]] | + | [[https://drive.google.com/file/d/1Ltw48ZOFn-qDi4RpH3-BPK6qBnIbFYWv/view?usp=drive_link|Stem Cell Tech Quote, which contains ordering instructions]] |
| Any new PIs joining 4DN recently who are not on this quote can be added to this quote. Please contact Takayo Sasaki <tsasaki@sdbri.org> | Any new PIs joining 4DN recently who are not on this quote can be added to this quote. Please contact Takayo Sasaki <tsasaki@sdbri.org> | ||
4dn/phase2/working_groups/cell_lines_and_samples.1652448523.txt.gz · Last modified: 2025/04/22 16:21 (external edit)